Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...
(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback